Bal Pharma Limited Stock Price Today (NSE: BALPHARMA)
Fundamental Score
Bal Pharma Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Bal Pharma Limited share price today is ₹106.21, down 7.20% on NSE/BSE as of 10 September 2026. Bal Pharma Limited (BALPHARMA) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹169.10 (Cr). The 52-week high for BALPHARMA share price is ₹124.60 and the 52-week low is ₹60.00. At a P/E ratio of 23.39x, BALPHARMA is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 7.87% and a debt-to-equity ratio of 1.94.
Bal Pharma Limited Share Price Chart — NSE/BSE Historical Performance
Bal Pharma Limited share price chart: 4.93% return over the past month. 52-week high ₹124.60, 52-week low ₹60.00.
Bal Pharma Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹120.00 | ₹124.60 | ₹105.05 | ₹106.21 | 6.90L (Cr) | |
| ₹95.10 | ₹114.45 | ₹95.10 | ₹114.45 | 7.83L (Cr) | |
| ₹93.78 | ₹97.60 | ₹93.00 | ₹95.38 | 1.27L (Cr) | |
| ₹87.73 | ₹95.00 | ₹86.00 | ₹92.69 | 1.57L (Cr) | |
| ₹87.70 | ₹89.69 | ₹87.10 | ₹87.73 | 8.21K (Cr) | |
| ₹85.50 | ₹90.50 | ₹85.13 | ₹87.71 | 55.53K (Cr) | |
| ₹84.10 | ₹88.88 | ₹84.10 | ₹85.65 | 14.66K (Cr) | |
| ₹85.00 | ₹87.70 | ₹84.22 | ₹85.45 | 23.15K (Cr) | |
| ₹84.80 | ₹87.30 | ₹84.10 | ₹85.00 | 4.82K (Cr) | |
| ₹85.89 | ₹86.03 | ₹84.17 | ₹84.80 | 6.20K (Cr) |
Bal Pharma Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹85.00 | ₹124.60 | ₹84.10 | ₹106.21 | +24.95% | |
| ₹88.40 | ₹93.00 | ₹82.05 | ₹85.00 | -3.85% | |
| ₹80.00 | ₹93.80 | ₹76.01 | ₹88.09 | +10.11% | |
| ₹92.30 | ₹92.30 | ₹78.10 | ₹79.55 | -13.81% | |
| ₹75.10 | ₹98.85 | ₹74.20 | ₹90.12 | +20.00% | |
| ₹60.20 | ₹81.30 | ₹60.20 | ₹76.21 | +26.59% | |
| ₹72.10 | ₹75.90 | ₹60.00 | ₹60.42 | -16.20% | |
| ₹70.62 | ₹81.50 | ₹66.40 | ₹75.28 | +6.60% | |
| ₹71.50 | ₹78.10 | ₹65.70 | ₹66.76 | -6.63% | |
| ₹76.89 | ₹79.50 | ₹69.00 | ₹73.32 | -4.64% | |
| ₹82.00 | ₹83.96 | ₹73.30 | ₹75.47 | -7.96% | |
| ₹83.49 | ₹90.30 | ₹80.00 | ₹82.45 | -1.25% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Bal Pharma Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Bal Pharma Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of BALPHARMA across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Excellent ROCE Performance (18.76%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 23.39 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (438.85%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (34.53%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Strong Cash Generation (₹29.20 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (50.86%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
6 factors identified
Below-Average Return on Equity (7.87%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Limited Growth History (4.46% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Earnings Growth (3.41% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Elevated Debt Levels (D/E: 1.94)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.
Weak Interest Coverage (1.35x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Limited Institutional Interest (FII+DII: 0.14%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Bal Pharma Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Bal Pharma Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Bal Pharma LimitedBal Pharma Limi...Selected✓ BALPHARMA • 524824 | 27.6/100 | ₹106.21₹106 | ₹169.10₹169.10 | 23.39Average 23.4 Average | 7.87%Poor 7.87% Poor | 18.76%Good 18.76% Good | 1.94Average 1.9 Average | 5.79%Good 5.79% Good | 4.46%Average 4.46% Average | 1.37% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1876.50₹1877 | ₹450228.65₹450228.65 | 37.23Average 37.2 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9467.50₹9468 | ₹250888.75₹250888.75 | 85.90Average 85.9 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4939.50₹4940 | ₹167182.32₹167182.32 | 78.91Average 78.9 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1138.70₹1139 | ₹113642.26₹113642.26 | 25.38Average 25.4 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1371.90₹1372 | ₹110828.94₹110828.94 | 32.87Average 32.9 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1941.10₹1941 | ₹104867.93₹104867.93 | 95.81Average 95.8 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1683.00₹1683 | ₹96839.82₹96839.82 | 26.30Average 26.3 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.70₹2101 | ₹96054.51₹96054.51 | 17.36Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1144.50₹1145 | ₹95565.75₹95565.75 | 29.58Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2293.70₹2294 | ₹94729.81₹94729.81 | 46.35Average 46.3 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price450228.65 Cr
- Divi's Laboratories Limited share price250888.75 Cr
- Torrent Pharmaceuticals Limited share price167182.32 Cr
- Zydus Lifesciences Limited share price113642.26 Cr
- Cipla Limited share price110828.94 Cr
Bal Pharma Limited PE Ratio History
Historical price-to-earnings ratio for BALPHARMA — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹4.56 | ₹73.32 | 16.1x |
| FY 2024 | ₹4.94 | ₹122.62 | 24.8x |
| FY 2023 | ₹1.67 | ₹100.05 | 59.9x |
| FY 2022 | ₹3.79 | ₹91.15 | 24.1x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Bal Pharma Limited Dividend History
Annual cash dividends paid by BALPHARMA — dividend yield 1.37%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹1.91 Cr |
| FY 2024 | ₹1.57 Cr |
| FY 2023 | ₹1.56 Cr |
| FY 2022 | ₹1.48 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Bal Pharma Limited Quarterly Performance
Latest quarterly metrics for BALPHARMA — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
34.53%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
438.85%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
4.46%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
5.79%
Compounded annual net profit growth over 5 years
Bal Pharma Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for BALPHARMA — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Bal Pharma Limited Financial Statements
Annual income statement, balance sheet and cash flow for Bal Pharma Limited (BALPHARMA) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Bal Pharma Limited
About BALPHARMA (Bal Pharma Limited)
Bal Pharma Ltd is a dynamic pharmaceutical entity focused on the development, manufacturing, and global distribution of a diverse range of pharmaceutical products. The company dist...inguishes itself through its dedication to innovation and its commitment to providing accessible healthcare solutions across multiple therapeutic areas. Bal Pharma operates with a multifaceted approach, encompassing the production of both finished formulations and active pharmaceutical ingredients (APIs), ensuring a vertically integrated supply chain and greater control over product quality. With a strong presence in both domestic and international markets, Bal Pharma seeks to address unmet medical needs and improve patient outcomes through the consistent delivery of high-quality, affordable medications. Bal Pharma's product portfolio caters to a wide spectrum of medical conditions, reflecting its understanding of evolving healthcare demands. Their offerings include prescription medications targeting various ailments, generic alternatives providing cost-effective treatment options, over-the-counter (OTC) products for self-care, and essential intravenous infusion products. The company also specializes in bulk drug manufacturing, supplying vital ingredients to other pharmaceutical companies. Through strategic brand development, Bal Pharma offers specialized products focused on key therapeutic areas such as anti-infectives, pain relief, respiratory health, and women's health, with established brands like Aziwin and Monogesic Plus Gel. Moreover, Bal Pharma is actively engaged in addressing the growing global prevalence of diabetes. The company's diabetic care product range reflects its commitment to improving the lives of individuals managing this chronic condition. By focusing on research and development, Bal Pharma continuously strives to introduce innovative and effective pharmaceutical solutions that enhance treatment outcomes and improve the overall quality of life for patients. Ultimately, Bal Pharma aims to be a reliable partner in healthcare, providing a comprehensive range of pharmaceutical products that meet the diverse needs of patients and healthcare professionals alike.
Company Details
Key Leadership
BALPHARMA Share Price: Frequently Asked Questions
What is the current share price of Bal Pharma Limited?
Bal Pharma Limited (BALPHARMA) trades at ₹106.21 on NSE and BSE. Market cap ₹169.10 (Cr). Educational data only.
What is the P/E ratio of Bal Pharma Limited?
Bal Pharma Limited has a P/E of 23.39x vs industry average 34.89x.
What is the Bull Run score for Bal Pharma Limited?
Bal Pharma Limited has a Bull Run score of 27.6/100 based on 25+ financial parameters.
Does Bal Pharma Limited pay dividends?
Bal Pharma Limited has a dividend yield of 1.37%. Past dividends don't guarantee future payments.
What is the ROE of Bal Pharma Limited?
Bal Pharma Limited has ROE of 7.87%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Bal Pharma Limited?
Bal Pharma Limited has debt-to-equity of 1.94.
Is Bal Pharma Limited a good investment?
Bull Run gives Bal Pharma Limited a score of 27.6/100. This is not investment advice — consult a SEBI-registered advisor.